Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECT: Vortioxetine for Cognitive Dysfunction in MDD
NCT01564862Phase 2Completed
- Sponsor
- Takeda
- Start
- Apr 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of vortioxetine in major depressive disorder (MDD), sponsored by Takeda. Started Apr 2012; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01564862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01564862.